Abraxis BioScience Company Description
Cancer patients will hopefully get a helpful shot in the arm thanks to Abraxis BioScience. Having spun off its generic injectable drug business, the company's oncology and research division is now devoted to developing its own line of injectable drugs starting with Abraxane, its patented version of cancer drug paclitaxel. Abraxis BioScience is working to quickly develop a market for Abraxane, which is approved for use in the treatment of metastatic breast cancer. The company owns manufacturing and development facilities in the US, Puerto Rico, and Switzerland. Chairman and CEO Patrick Soon-Shiong holds more than 80% of the company.
View the Comprehensive Company Description for Abraxis BioScience
The Company Description provides a historical perspective of Abraxis BioScience's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Abraxis BioScience's evolution in the marketplace.
